ChemicalBook > CAS DataBase List > GLP-1 receptor agonist 1

GLP-1 receptor agonist 1

Product Name
GLP-1 receptor agonist 1
CAS No.
2212020-52-3
Chemical Name
GLP-1 receptor agonist 1
Synonyms
LY3502970;OWL 833;Ogerlon;Orforglipron;0rforglipron;Orforglipron（LY3502970）;LY3502970 (Orforglipron);Orforglipron, 10 mM in DMSO;Research Grade Orforglipron;Orforglipron，PhEur/USP(DMF)
CBNumber
CB45419742
Molecular Formula
C48H48F2N10O5
Formula Weight
882.97
MOL File
2212020-52-3.mol
More
Less

GLP-1 receptor agonist 1 Property

Density 
1.50±0.1 g/cm3(Predicted)
storage temp. 
Store at -20°C
solubility 
DMSO : 125 mg/mL (141.57 mM)
form 
Solid
pka
7.33±0.20(Predicted)
color 
Off-white to light yellow
InChIKey
USUWIEBBBWHKNI-BBGRWQLENA-N
More
Less

Hazard and Precautionary Statements (GHS)

More
Less

N-Bromosuccinimide Price

ChemScene
Product number
CS-0043632
Product name
GLP-1receptoragonist1
Purity
99.42%
Packaging
5mg
Price
$1100
Updated
2021/12/16
ChemScene
Product number
CS-0043632
Product name
GLP-1receptoragonist1
Purity
99.42%
Packaging
10mg
Price
$1800
Updated
2021/12/16
ChemScene
Product number
CS-0043632
Product name
GLP-1receptoragonist1
Purity
99.42%
Packaging
25mg
Price
$3900
Updated
2021/12/16
ChemScene
Product number
CS-0043632
Product name
GLP-1receptoragonist1
Purity
99.42%
Packaging
50mg
Price
$6500
Updated
2021/12/16
ChemScene
Product number
CS-0043632
Product name
GLP-1receptoragonist1
Purity
99.42%
Packaging
100mg
Price
$9950
Updated
2021/12/16
More
Less

GLP-1 receptor agonist 1 Chemical Properties,Usage,Production

Description

Orforglipron (LY3502970) (GLP-1 receptor agonist 1) is  GLP-1 receptor agonist extracted from patent WO2018056453A1, Compound 67.

History

Orforglipron is an oral, non-peptide, small-molecule glucagon-like peptide-1 receptor agonist developed by Eli Lilly and Company as a weight-loss drug. Currently, the drug is still in Phase III clinical trials and has not yet received approval from the U.S. Food and Drug Administration (FDA). Eli Lilly's CEO expects the FDA to approve its investigational oral weight-loss drug, orforglipron, by March 2026, and to submit an application for the treatment of type 2 diabetes by the end of 2026.

Uses

Glucagon-like peptide-1 (GLP-1) agonists (also known as GLP-1 receptor agonists, incretin mimetics, or GLP-1 analogs) represent a class of medications used to treat type 2 diabetes mellitus and, in some cases, obesity.

in vivo

Orforglipron (0.94-4.8 nM in plasma concentration, i.v., or 0.05-0.1 mg/mL, i.g. for 5 days) suppresses food intake in a dose-dependent manner, promotes insulin secretion and decreases blood glucose in cynomolgus monkey model[1].
Orforglipron (0.05-1.35 mg/kg, i.g.) reaches Cmax 2 hours after administration at all doses, exhibits proportional ratio of increase in plasma drug exposure to dose increase, indicates a dose-dependent absorption in the gastrointestinal tract[1].

Pharmacokinetic Analysis of Orforglipron in cynomolgus monkey [1]

routeDose (mg/kg)Tmax (h)Cmax (ng/mL)AUC0-24h (ng·h/mL)
i.g.0.052.04.7823.7
i.g.0.152.020.7135
i.g.0.452.032.0208
i.g.1.352.01481040
Animal Model:cynomolgus monkey model[1]
Dosage:0.9-4.8 nM; 0.05-0.1 mg/mL
Administration:continuous i.v. administration for 30 minutes until a plasma concentration of 0.9-4.8 nM at steady state;
i.g. for 5 days with dose of 0.05-0.1 mg/mL
Result:Increased insulin secretion and decreased plasma-glucose. Suppressed food intake in a dose-dependent manner.

GLP-1 receptor agonist 1 Preparation Products And Raw materials

Raw materials

Preparation Products

More
Less

GLP-1 receptor agonist 1 Suppliers

China 189 United States 6 Global 195
Bayee Biotech (Anqing) Co., Ltd.
Tel
0556-5032306 18917961636
Email
wtx@bayeebio.com
Country
China
ProdList
239
Advantage
61
Hangzhou Go Top Peptide Biotech
Tel
15397062932
Email
sales1@gotopbio.com
Country
China
ProdList
2923
Advantage
58
Nantong QuanYi Biotechnology Co., Ltd
Tel
0513-66337626 18051384581
Email
sales@chemhifuture.com
Country
China
ProdList
5929
Advantage
58
Chengdu Yunyidian Biological Technology Co.,Ltd
Tel
17621298782
Email
sales@cdyunyidian.com
Country
China
ProdList
217
Advantage
58
Chengdu DingDang Pharmaceutical Co., Ltd.
Tel
028-86040038 13980902949;
Fax
028-85149890
Email
market@dingdangchem.com
Country
China
ProdList
1853
Advantage
55
Zhejiang Brunova Technology Co., Ltd.
Tel
13735468882 17857108485
Email
info@zjbrunova.com
Country
China
ProdList
76
Advantage
58
Chunchuang (Wuhan) Technology Co., Ltd
Tel
15727060112
Email
yutianchun2007@126.com
Country
China
ProdList
9814
Advantage
58
Nantong Nuotai Biomedical Technology Co., Ltd.
Tel
0513-82206272 17706270880
Email
2057095228@qq.com
Country
China
ProdList
173
Advantage
58
Nanjing Lebang Pharmaceutical Technology Co., Ltd
Tel
18860950986
Email
tangmanman@lebangpharma.com
Country
China
ProdList
650
Advantage
58
Changzhou Xuanming Pharmaceutical Technology Co., Ltd.
Tel
0519-05198552532 15995069468
Fax
0519-85190960
Email
29526743@qq.com
Country
China
ProdList
300
Advantage
58
More
Less

View Lastest Price from GLP-1 receptor agonist 1 manufacturers

RongNa Biotechnology Co.,Ltd
Product
Orforglipron（LY3502970） 2212020-52-3
Price
US $10.00/ASSAYS
Min. Order
1ASSAYS
Purity
99%
Supply Ability
1 ton
Release date
2025-11-21
Shaanxi Dideu New Materials Co. Ltd
Product
Glufosinate-ammonium 2212020-52-3
Price
US $0.00-0.00/KG
Min. Order
1KG
Purity
98
Supply Ability
10000KGS
Release date
2025-11-20
Shaanxi Dideu New Materials Co. Ltd
Product
Orforglipron 2212020-52-3
Price
US $0.00-0.00/KG
Min. Order
1KG
Purity
98
Supply Ability
10000KGS
Release date
2025-11-20

2212020-52-3, GLP-1 receptor agonist 1Related Search:

(S,E)-1-(4-fluoro-1-methyl-1H-indazol-5-yl)-3-(2-(4-fluoro-3,5-dimethylphenyl)-4-methyl-4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridin-3-yl)-1-(2-hydroxyvinyl)urea \\ 5-[(S)-2,2-Dimethyltetrahydro-2H-pyran-4-yl]-1-[(1S,2S)-2-methyl-1-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)cyclopropyl]-1H-indole-2-carboxylic Acid 1H-Indole-2-carboxamide, N-methyl-N-phenyl-5-[(4S)-tetrahydro-2,2-dimethyl-2H-pyran-4-yl]- (R)-1-(4-fluoro-1-methyl-1H-indazol-5-yl)-3-(2-(4-fluoro-3,5-dimethylphenyl)-4-methyl-4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridin-3-yl)-1,3-dihydro-2H-imidazol-2-one 3-((1S,2R)-1-(5-((R)-2,2-dimethyltetrahydro-2H-pyran-4-yl)-2-((R)-3- (3-(4-fluoro-1-methyl-1H-indazol-5-yl)-2-oxo-2,3-dihydro-1Himidazol-1-yl)-2-(4-fluoro-3,5-dimethylphenyl)-4-methyl-4,5,6,7- tetrahydro-2H-pyrazolo[4,3-c]pyridine-5-carbonyl)-1H-indol-1-yl)-2- methylcyclopropyl)-1,2,4-oxadiazol-5(4H)-one Ly3502970

  • 1,2,4-Oxadiazol-5(2H)-one, 3-[(1S,2S)-1-[2-[[(4S)-2-(4-fluoro-3,5-dimethylphenyl)-3-[3-(4-fluoro-1-methyl-1H-indazol-5-yl)-2,3-dihydro-2-oxo-1H-imidazol-1-yl]-2,4,6,7-tetrahydro-4-methyl-5H-pyrazolo[4,3-c]pyridin-5-yl]carbonyl]-5-[(4S)-tetrahydro-2,2-dimethyl-2H-pyran-4-yl]-1H-indol-1-yl]-2-methylcy...
  • LY3502970
  • GLP-1 receptor agonist 1 USP/EP/BP
  • Orforglipron
  • Orforglipron（LY3502970）
  • LY3502970 (Orforglipron)
  • 3-((1S,2S)-1-(5-((S)-2,2-dimethyltetrahydro-2H-pyran-4-yl)-2-((S)-3-(3-(4-fluoro-1-methyl-1H-indazol-5-yl)-2-oxo-2,3-dihydro-1H-imidazol-1-yl)-2-(4-fluoro-3,5-dimethylphenyl)-4-methyl-4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridine-5-carbonyl)-1H-indol-1-yl)-2-methylcyclopropyl)-1,2,4-oxadiazol-5(4H)-one
  • OWL 833
  • LY3502970|||GLP-1 receptor agonist 1
  • 3-((1S,2S)-1-(5-((S)-2,2-Dimethyltetrahydro-2H-pyran-4-yl)-2-((S)-3-(3-(4-fluoro-1-methyl-1H-indazol-5-yl)-2-oxo-2,3-dihydro-1H-imidazol-1-yl)-2-(4-fluoro-3,5-dimethylphenyl)-4-methyl-4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridine-5-carbonyl)-1H-indol-1-yl
  • 1,2,4-Oxadiazol-5(2H)-one, 3-[(1S,2S)-1-[2-[[(4S)-2-(4-fluoro-3,5-dimethylphenyl)-3-[3-(4-fluoro-1-methyl-1H-indazol-5-yl)-2,3-dihydro-2-oxo-1H-imidazol-1-yl]-2,4,6,7-tetrahydro-4-methyl-5H-pyrazolo[4,3-c]pyridin-5-yl]carbonyl]-5-[(4S)-tetrahydro-2,2-dimethyl-2H-pyran-4-yl]-1H-indol-1-yl]-2-methylcyclopropyl]-
  • Orforglipron, 10 mM in DMSO
  • Research Grade Orforglipron
  • 1,2,4-Oxadiazol-5(2H)-one,3-[(1S,2S)-1-[2-[[(4S)-2-(4-fluoro-3,5-dimethylphenyl)-3-[3-(4-fluoro-1-methyl-1H-indazol-5-yl)-2,3-dihydro-2-oxo-1H-imidazChemicalbookol-1-yl]-2,4,6,7-tetrahydro-4-methyl-5H-pyrazolo[4,3-c]pyridin-5-yl]carbonyl]-5-[(4S)-tetrahydro-2,2-dimethyl-2H-pyran-4-yl]-1H-indol-1-yl]-2-methylcy
  • 1,2,4-Oxadiazol-5(2H)-one,3-[(1S,2S)-1-[2-[[(4S)-2-(4-fluoro-3,5-dimethylphenyl)-3-[3-(4-fluoro-1-methyl-1H-indazol-5-yl)-2,3-dihydro-2-oxo-1H-imidazChemicalbookol-1-yl]-2,4,6,7-tetrahydro-4-methyl-5H
  • 0rforglipron
  • 3-[(1S,2S)-1-[2-[[(4S)-2-(4-fluoro-3,5-dimethylphenyl)-3-[3-(4-fluoro-1-methyl-1H-indazol-5-yl)-2,3-dihydro-2-oxo-1H-imidazol-1-yl]-2,4,6,7-tetrahydro-4-methyl-5H-pyrazolo[4,3-c]pyridin-5-yl]carbonyl]-5-[(4S)-tetrahydro-2,2-dimethyl-2H-pyran-4-yl]-1H-indol-1-yl]-2-methylcyclopropyl]-1,2,4-Oxadiazol-5(2H)-one
  • Ogerlon
  • Orforglipron，PhEur/USP(DMF)
  • Orforglipron raw materials,Peptide customization
  • Orforglipron/GLP-1 receptor agonist 1
  • 3-((1S,2S)-1-(5-((S)-2,2-dimethyltetrahydro-2H-pyran-4-yl)-2-((S)-3-(3-(4-fluoro-1-methyl-1H-indazol-5-yl)-2-oxo-2,3-dihydro-1H-imidazol-1-yl)-2-(4-fluoro-3,5-dimethylphenyl)-4-methyl-4,5,6,7-tetrahyd
  • 2212020-52-3
  • C48H48F2N10O5
  • 1
  • ADVANCED INT.
  • API